Filing Details

Accession Number:
0000950170-23-051899
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-04 16:05:34
Reporting Period:
2023-10-02
Accepted Time:
2023-10-04 16:05:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1088856 Corcept Therapeutics Inc CORT Pharmaceutical Preparations (2834) 770487658
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1698310 Sean Maduck C/O Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park CA 94025
See Remarks No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-02 3,031 $3.02 76,641 No 4 M Direct
Common Stock Disposition 2023-10-02 3,031 $27.24 73,610 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2023-10-02 3,031 $0.00 3,031 $3.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,969 2024-02-06 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,000 Indirect See Footnote
Common Stock 10,000 Indirect See Footnote
Footnotes
  1. Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
  3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $27.24 to $27.255. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
  4. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  5. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  6. Fully exercisable.